This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

9 Apr 2013

Brintellix could provide alternative treatment to MDD patients

A Danish study has found Brintellix could be an effective treatment for those with MDD.

Adult patients with major depression (MDD) and poor responses to SSRI or SNRI therapy could benefit from a new treatment known as Brintellix.
A Danish study entitled Revive has confirmed positive results for the drug when it was pitted against agomelantine for those with MDD.
The multimodal antidepressant is thought to work through a combination of receptor activity and re-uptake inhibition and was said to be "statistically superior" to agomelantine by 2.2 MADRS points.
Head of research and development at Lundbeck Anders Gersel Pedersen said: "Patients with inadequate response to current SSRI or SNRI therapies represent a large proportion of patients suffering from major depression."
The aim of the study was to compare the tolerability of flexible dose treatment with Brintelix against agomelatine.
There were fewer patient withdrawals in the Brintellix group at 5.9 per cent, compared to 9.5 per cent for the agomelatine group.
Estimates suggest as many as a third of the world's population will be affected by at least one episode of MDD during their lifetime.

Related News